JP2022535093A5 - - Google Patents
Info
- Publication number
- JP2022535093A5 JP2022535093A5 JP2021571882A JP2021571882A JP2022535093A5 JP 2022535093 A5 JP2022535093 A5 JP 2022535093A5 JP 2021571882 A JP2021571882 A JP 2021571882A JP 2021571882 A JP2021571882 A JP 2021571882A JP 2022535093 A5 JP2022535093 A5 JP 2022535093A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- dimethyltryptamine
- enriched mixture
- pharmaceutically acceptable
- mixture according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907871.6 | 2019-06-03 | ||
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535093A JP2022535093A (ja) | 2022-08-04 |
| JP2022535093A5 true JP2022535093A5 (https=) | 2023-05-30 |
| JP7523474B2 JP7523474B2 (ja) | 2024-07-26 |
Family
ID=67385960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571882A Active JP7523474B2 (ja) | 2019-06-03 | 2020-06-02 | 重水素化された又は部分的に重水素化されたｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11771681B2 (https=) |
| EP (2) | EP3826632B1 (https=) |
| JP (1) | JP7523474B2 (https=) |
| KR (2) | KR20220034061A (https=) |
| CN (1) | CN114096246B (https=) |
| AU (1) | AU2020286709B2 (https=) |
| BR (1) | BR112021024333A2 (https=) |
| CA (2) | CA3142290C (https=) |
| DK (1) | DK3826632T3 (https=) |
| EA (1) | EA202193338A1 (https=) |
| ES (1) | ES2922101T3 (https=) |
| GB (4) | GB201907871D0 (https=) |
| HR (1) | HRP20220837T8 (https=) |
| HU (1) | HUE059439T2 (https=) |
| IL (1) | IL288617B2 (https=) |
| MX (1) | MX2021014728A (https=) |
| PL (1) | PL3826632T3 (https=) |
| PT (1) | PT3826632T (https=) |
| TW (1) | TWI860478B (https=) |
| WO (1) | WO2020245133A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| BR112022015379A2 (pt) | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| MX2022014900A (es) * | 2020-06-02 | 2023-03-27 | Small Pharma Ltd | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. |
| GB2605144A (en) * | 2021-03-22 | 2022-09-28 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| JP7422474B2 (ja) * | 2020-08-28 | 2024-01-26 | サイビン ユーケー リミテッド | 注射用製剤 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP4255422A4 (en) * | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| JP2024517738A (ja) * | 2021-04-26 | 2024-04-23 | アタイ セラピューティクス， インコーポレイテッド | 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| CA3217559A1 (en) * | 2021-05-05 | 2022-11-10 | Kamaluddin Abdur-Rashid | Catalytic tryptamine processes and precursors |
| KR20240009433A (ko) * | 2021-05-17 | 2024-01-22 | 사이빈 아이알엘 리미티드 | 실로시빈의 제형 |
| CA3218110A1 (en) * | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| US20240286998A1 (en) * | 2021-06-02 | 2024-08-29 | Saint Joseph's University | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| KR20240058859A (ko) | 2021-08-12 | 2024-05-03 | 쿨레온 엘엘씨 | 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법 |
| EP4392028A4 (en) * | 2021-08-23 | 2025-09-24 | Alexander Shulgin Res Institute Inc | DEUTERATED EMPATHOGENS |
| EP4392027A4 (en) | 2021-08-23 | 2025-07-23 | Alexander Shulgin Res Institute Inc | FLUORINATED EMPATHOGENS |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| WO2023076135A1 (en) * | 2021-10-29 | 2023-05-04 | Psilera Inc. | N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| EP4433049A1 (en) | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| CA3246274A1 (en) * | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | METHODS OF ADMINISTRATING PSYCHEDELIC MEDICINES BY INHALATION AND SYSTEMS FOR IMPLEMENTING THESE METHODS |
| AU2023269880A1 (en) | 2022-05-10 | 2024-01-18 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| CN121194779A (zh) | 2023-03-31 | 2025-12-23 | 赛本英国有限公司 | 包含单胺抗抑郁剂和短效致幻剂的组合 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| AU1928892A (en) | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| EP1292282A2 (en) | 2000-06-16 | 2003-03-19 | RTP Pharma Inc. | Improved injectable dispersions of propofol |
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| CA2666149A1 (en) | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| EP2209380A4 (en) | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| CN109251151A (zh) * | 2017-07-12 | 2019-01-22 | 北京广为医药科技有限公司 | N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| HUE069534T2 (hu) | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| MX2021010198A (es) | 2019-02-27 | 2021-09-21 | Univ California | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| EP4192451A4 (en) | 2020-08-05 | 2024-08-14 | Universitätsspital Basel | METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| JP7422474B2 (ja) | 2020-08-28 | 2024-01-26 | サイビン ユーケー リミテッド | 注射用製剤 |
| EP4221682A2 (en) | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
-
2019
- 2019-06-03 GB GBGB1907871.6A patent/GB201907871D0/en not_active Ceased
-
2020
- 2020-06-02 JP JP2021571882A patent/JP7523474B2/ja active Active
- 2020-06-02 CA CA3142290A patent/CA3142290C/en active Active
- 2020-06-02 IL IL288617A patent/IL288617B2/en unknown
- 2020-06-02 GB GB2107702.9A patent/GB2592822B/en active Active
- 2020-06-02 KR KR1020217043410A patent/KR20220034061A/ko not_active Ceased
- 2020-06-02 GB GB2100807.3A patent/GB2586940B/en active Active
- 2020-06-02 WO PCT/EP2020/065244 patent/WO2020245133A1/en not_active Ceased
- 2020-06-02 KR KR1020247030292A patent/KR20240142567A/ko not_active Ceased
- 2020-06-02 US US16/890,664 patent/US11771681B2/en active Active
- 2020-06-02 US US17/616,345 patent/US12076311B2/en active Active
- 2020-06-02 AU AU2020286709A patent/AU2020286709B2/en active Active
- 2020-06-02 MX MX2021014728A patent/MX2021014728A/es unknown
- 2020-06-02 DK DK20731372.7T patent/DK3826632T3/da active
- 2020-06-02 PT PT207313727T patent/PT3826632T/pt unknown
- 2020-06-02 EP EP20731372.7A patent/EP3826632B1/en active Active
- 2020-06-02 BR BR112021024333A patent/BR112021024333A2/pt unknown
- 2020-06-02 GB GB2008303.6A patent/GB2585978B/en active Active
- 2020-06-02 CN CN202080050439.9A patent/CN114096246B/zh active Active
- 2020-06-02 EA EA202193338A patent/EA202193338A1/ru unknown
- 2020-06-02 PL PL20731372.7T patent/PL3826632T3/pl unknown
- 2020-06-02 HR HRP20220837TT patent/HRP20220837T8/hr unknown
- 2020-06-02 EP EP22173907.1A patent/EP4062910B1/en active Active
- 2020-06-02 ES ES20731372T patent/ES2922101T3/es active Active
- 2020-06-02 HU HUE20731372A patent/HUE059439T2/hu unknown
- 2020-12-23 CA CA3104072A patent/CA3104072C/en active Active
-
2021
- 2021-06-01 TW TW110119792A patent/TWI860478B/zh active
-
2024
- 2024-07-22 US US18/779,611 patent/US20240374565A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535093A5 (https=) | ||
| JP2023527575A5 (https=) | ||
| JP2021505575A5 (https=) | ||
| JP2003503450A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| JP2022514089A5 (https=) | ||
| JP2016510317A5 (https=) | ||
| JP2023103256A (ja) | 非ラセミ混合物およびその使用 | |
| JP2015526458A5 (https=) | ||
| RU2005104418A (ru) | Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин | |
| JP2004519469A5 (https=) | ||
| JPWO1993011765A1 (ja) | （＋）アポビンカミン酸２−ニトロキシエチルエステルの新規な用途 | |
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| IL273169B1 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| JP2023550149A5 (https=) | ||
| JP7801365B2 (ja) | 環状ケトン系化合物の新たな使用 | |
| CN104010636A (zh) | 三环化合物、包含它们的组合物及其用途 | |
| JP2019529460A5 (https=) | ||
| CN103889409A (zh) | N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案 | |
| JP2024542984A5 (https=) | ||
| JP2020536048A5 (https=) | ||
| TWI335220B (en) | Use of caffeic acid phenethyl ester for manufacturing a medicament for treating neurodegenerative and cardiovascular disorders | |
| JP2023552862A5 (https=) | ||
| JP2024500632A5 (https=) | ||
| JP2020502106A5 (https=) |